FEEDBACK ON THIS REPORT

"This report is highly regarded in the industry.  I sit on one of the IMC operational committees, where we often discuss access to therapies.  In speaking with a colleague from [MFR], he mentioned that his company also purchases the CRaFT report. Lately, I have referenced the CRaFT report to help support discussions on access to drugs in certain provinces." 

– Patient Access and Government Affairs Manager
Toronto-based Pharmaceutical Company

"The Canadian Reimbursement and Forecasting Timelines (CRaFT) report is a critical tool that we leverage in Canadian oncology market access discussions with Global teams as well as forecasting. The report provides objective data and timelines with each step throughout the entire reimbursement process, identifies key trends, and summarizes information in an easy-to-read format. I would highly recommend this report if you are looking for a comprehensive overview of the current Canadian reimbursement landscape."

– Director, Market Access
Toronto-Based Pharmaceutical Company

ORDER NOW

2024 Edition of CRaFT Reports & Subscription

MORSE Consulting Inc. is delighted to present the 2024 edition of the Canadian Reimbursement and Forecasting Timelines (CRaFT) subscription and the new Drugs for Rare Diseases (DRD) Sub-Report!

Download a Sample of the Report.

A CRaFT Subscription provides clients with access to in-depth public market access volume and timeline analyses using MORSE’s robust public payer dataset, paired with insights tapped from MORSE’s unparalleled HTA and public payer expertise. 

The 2024 CRaFT Subscription includes access to the following:  

  • 2024 edition of CRaFT Report, which includes analysis of: 
    • CADTH volume & timeline metrics 
    • CADTH & INESSS alignment in recommendations 
    • pCPA volume & timeline metrics, and negotiation trends 
    • Provincial funding volume & timeline metrics 
    • Data stratification by Oncology, Non-Oncology, Biosimilars, and Others 
    • NEW Targeted Negotiation Process (TNP) analysis  
  • NEW Monthly Market Access Update, which includes a monthly analysis of CADTH and pCPA metrics and a summary of files moving through the market access process
  • NEW Mid-year Update of listing data from BC, AB, ON, and QC

Additionally, this year’s add-ons for purchase include:  

  • Drug for Rare Diseases (DRD) sub-report  
  • NEW “customizable” indication-specific sub-report 

Together, these reports and insights are a comprehensive source of reimbursement timeline information to assist companies with their upcoming Canadian launch.

  • Canadian Reimbursement Forecasting Timelines Report
  • Canadian Reimbursement Forecasting Timelines Report 1

For further information on content and pricing, please complete the form below.

This report is only available to pharmaceutical companies to assist with their reimbursement forecasting and planning.


We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Canadian Reimbursement and Forecasting Timelines Report, 2024